Edwards Lifesciences (EW) Stock
Heart valve and critical care monitoring leader. Here's the price, business snapshot, and what's worth knowing about Edwards Lifesciences in May 2026.
Edwards Lifesciences Corporation (EW) is a medical-technology company focused on heart valves and critical-care monitoring. It is best known for the Sapien transcatheter aortic valve replacement (TAVR) system and a broad range of surgical valves and haemodynamic monitoring products. Investors typically monitor Edwards for its leadership in structural heart therapies, clinical-driven innovation, and exposure to an ageing population that boosts demand for valve procedures. Revenue growth is linked to procedure volumes, reimbursement environments and the success of clinical trials and new indications. The company invests in R&D and selective acquisitions to extend its portfolio and geographic reach. Key risks include competition, regulatory and reimbursement shifts, and sensitivity to elective-procedure cycles. This is general educational information only and not personalised financial advice; values can rise or fall and past performance is not a reliable guide. Consider your own circumstances or consult a financial adviser before making investment decisions.
Why It's Moving
EW is edging higher as analysts keep a constructive stance on Edwards Lifesciences despite a mixed setup.
- Analyst sentiment remains constructive, with the stock still carrying a moderate-buy consensus and a double-digit implied upside, reinforcing the view that the market expects continued operating momentum.
- Recent forecast updates show only modest changes in price expectations, which indicates analysts are not seeing a major shift in the company’s underlying growth story.
- The stock has been trading near the top of its recent range, so moves are being driven more by valuation and sentiment than by a fresh earnings surprise or product catalyst.
EW is edging higher as analysts keep a constructive stance on Edwards Lifesciences despite a mixed setup.
- Analyst sentiment remains constructive, with the stock still carrying a moderate-buy consensus and a double-digit implied upside, reinforcing the view that the market expects continued operating momentum.
- Recent forecast updates show only modest changes in price expectations, which indicates analysts are not seeing a major shift in the company’s underlying growth story.
- The stock has been trading near the top of its recent range, so moves are being driven more by valuation and sentiment than by a fresh earnings surprise or product catalyst.
When is the next earnings date for EDWARDS LIFESCIENCES CORP (EW)?
The next earnings date for EW is not confirmed in the provided data, but Edwards Lifesciences has typically reported first-quarter results in late April or early May. Based on that historical pattern, the next report would most likely cover Q2 2026 and be released around late July 2026. The analyst consensus shown is Buy, with no hold or sell ratings indicated.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Edwards Lifesciences stock with a target price of $95.77, indicating potential growth.
Financial Health
Edwards Lifesciences is performing well with strong profits and cash flow, supporting its growth potential.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring EW
Wearable Tech IP Wars: What Investors Should Know
Masimo's lawsuit against U.S. Customs, following a reversal of an import ban on Apple Watches, highlights the fierce competition over intellectual property in wearable health. This theme focuses on the medical technology companies and competitors poised to benefit from the ongoing patent battles in the lucrative health-monitoring device market.
Published: August 21, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Leader in TAVR
Edwards holds a strong position in transcatheter aortic valve replacement; adoption and expanded indications can support growth, though procedure volumes can fluctuate.
Clinical-driven innovation
Ongoing trials and new device launches are central to long-term prospects, but regulatory outcomes and trial timing can influence performance.
Demographics & reach
An ageing global population and geographic expansion present opportunities, while reimbursement and local regulation remain important considerations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
